![](bg62.jpg)
97
pancreatic cancer treatment: exploiting the novel, therapeutic target NQO1.
Cancer. Biol. Ther. 4: 95-102, 2005.
PARDEE, A.B., LI, Y.Z., LI, C.J. Cancer Therapy with ß-Lapachone. Curr.
Cancer Drug Targets 2: 227-242, 2002.
PARONE P.A., JAMES D., MARTINOU J.C. Mitochondria: regulating the
inevitable. Biochimie 84: 105–111, 2002.
PELICANO, H., CARNEY, D., HUANG, P. ROS stress in cancer cells and
therapeutic implications. Drug Resist. Updates. 7: 97-110, 2004.
PERES, C. M. & CURI, R., Como Cultivar Células, Guanabara Koogan, Rio
de Janeiro, 2005.
PICCART-GEBHART M. J., PROCTER M. LEYLAND-JONES B.
GOLDHIRSCH, A. UNTCH, M. SMITH, I. GIANNI, L. BASELGA, J. BELL, R.
JACKISCH, C. CAMERON, D. DOWSETT, M. BARRIOS, C. H. STEGER, G.
HUANG, C. S ANDERSSON, M. INBAR, M. LICHINITSER, M. LÁNG, I. NITZ,
U. IWATA, H. THOMSSEN, C. LOHRISCH, C. SUTER, T. M. RÜSCHOFF, J.
SÜT , T. GREATOREX, V. WARD, C. STRAEHLE, C. MCFADDEN, E. DOLCI,
M. S. GELBER, R. D. Trastuzumab after adjuvant chemotherapy in HER2-
positive breast cancer. N Engl J Med. 353:1659-1672, 2005.
PINK, J.J., PLANCHON, S.M., TAGLIARINO, C., VARNES, M.E., SIEGEL, D.,
BOOTHMAN, D.A. NAD(P)H: quinone oxidoreductase activity is the principal
determinant of beta-lapachone cytotoxicity. J. Biol. Chem. 275: 5416-5424,
2000 (b).
PINK, J.J., WUERZBERGER-DAVIS, S., TAGLIARINO, C., PLANCHON, S.M.,
YANG, X., FROELICH, C.J., BOOTHMAN, D.A. Activation of a cysteine
protease in MCF-7 and T47D breast cancer cells during beta-lapachone-
mediated apoptosis. Experimental Cell Research 255: 144-155, 2000 (a).
PLANCHON, S. M.; WUERZBERGER, S.; FRYDMAN, B.; WITIAK, D.T.;
HUTSON, P.; CHURCH, D.R.; WILDING, G.; BOOTHMAN, D.A. ß-Lapachone-